Salix expects lackluster sales as it speeds to fix inventory issues

Carly Helfand

Back in November, revealed some that had skewed perceived demand for some of its products–and possibly cost it a deal with Allergan in the process. Now, the company says it's moving to fix the problem quickly. But in the meantime, its top line will pay the price.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS